U.S. Markets open in 6 hrs 19 mins

ProQR Therapeutics N.V. (PRQR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.32-0.14 (-2.17%)
At close: 4:00PM EDT

ProQR Therapeutics N.V.

Zernikedreef 9
Leiden 2333 Ck
31 88 166 7000

Full Time Employees150

Key Executives

NameTitlePayExercisedYear Born
Mr. Daniel Anton de BoerCEO & Member of Management Board842.71kN/A1983
Mr. Gerard PlatenburgCo-Founder & Chief Innovation OfficerN/AN/A1964
Ms. Smital Shah M.B.A.Chief Bus. & Financial OfficerN/AN/A1976
Dr. Naveed K. Shams M.D., Ph.D.Chief Scientific OfficerN/AN/A1956
Ms. Sarah Cue KielyVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Ms. Sheila SponseleeVP of HRN/AN/AN/A
Mr. Bart KleinSr. VP of Intellectual PropertyN/AN/AN/A
Ms. Bianca MattheeHead of Manufacturing and PharmaceuticsN/AN/AN/A
Mr. Aniz Girach M.D.Chief Medical OfficerN/AN/A1967
Ms. Tiffany BurtHead of Commercial & VPN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase I/II aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Corporate Governance

ProQR Therapeutics N.V.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.